November 25, 2019 (Sarasota, FL) – Dr. Daniel P. Stein, founder and medical director of Neurology of Cannabis located in Sarasota, FL, has been recognized as a peer reviewer by The American Journal of Endocannabinoid Medicine.
Designed to help educate physicians on the endocannabinoid system and the impact of medical cannabis on it, the Journal presents peer reviewed, clinically relevant research, independent medical studies, case reports and evidence-based data.
Dr. Stein’s peer review of a study conducted assessing the levels of endocannabinoids found in children with autism concluded that the evidence presented, “supports the theory that disruption of the endocannabinoid system may play a role in autism spectrum disorder,” he said in his review.
The Journal is considered the de facto source of reliable, scientific information for the impact of medical cannabis on the endocannabinoid system, and Dr. Stein’s appointment as a peer reviewer is a testament to his status and credibility in the industry.
One of the Journal’s editors, Jahan Marcu, Ph.D., contacted Dr. Stein, seeking his input as the Journal aims to present and interpret the currently available authoritative research, while stimulating questions regarding the role of medical cannabis in all forms, as a growing methodology in the field of treatment and patient care.
The Journal collaborated with Havas ECS, founded earlier this year by Havas Health & You, to launch a full spectrum education program for the medical and legal communities, beginning with a conference, November 15 in New York. Featured speakers included the world’s leading industry and medical experts. The collaboration expects to add a series of education events and curriculums throughout 2020.
About Dr. Stein
Neurology of Cannabis offers patients expert medical marijuana treatment options through Dr. Daniel P. Stein. For more than a quarter of a century Dr. Stein has used his medical training in neurology to assist patients in their journey to greater health and well-being.
Dr. Stein completed fellowship training at the prestigious National Institute of Health in Immunology of Neuromuscular Disease. He was a resident at the Cleveland Clinic Foundation and served out his medical internship at the Mt. Sinai Medical Center in Cleveland. He is a board-certified physician with more than 25 years of experience practicing neurology. For more information, visit https://www.neurologyofcannabis.com/
About the American Journal of Endocannabinoid Medicine
The objective of the American Journal of Endocannabinoid Medicine is to help educate physicians on the endocannabinoid system and the impact of medical cannabis on it. This information is presented via peer reviewed, clinically relevant research, independent medical studies, case reports and evidence-based data.
AJEM, launched in October, aims to present / interpret the currently available authoritative research, while stimulating questions regarding the role of medical cannabis in all forms, as a growing methodology in the field of treatment and patient care. The intent of AJEM is to be utilized as a clinical resource and contribute to the examination and overall discussion of medical cannabis.
For more information, visit www.ajendomed.com.